LG Chem is expanding its reproductive health awareness campaign, previously targeted at employees, to the general public. With declining birth rates and advanced maternal age becoming societal issues, the initiative aims to promote the importance of managing reproductive health not only when preparing for pregnancy but also in daily life.
LG Chem announced on November 17 that it conducted a 'Reproductive Health Base Camp' campaign for Seoul City Hall officials in collaboration with the Korean Society of Reproductive Medicine. The event was designed to correct misconceptions about reproductive health, including fertility management and healthy pregnancy preparation, and to emphasize the importance of everyday management. The event featured a talk concert with specialists, along with health quizzes and reproductive health consultation booths.
This campaign began at LG Group's Magok, Yeouido, and Seoul Station offices, targeting employees. So far, over 3,000 participants have attended events such as the talk concert. LG Chem plans to increase external participation and continue the campaign in various locations following the event at Seoul City Hall.
Kim Sung-ho, head of LG Chem's Specialty Care Division, stated, "We planned this campaign to provide reliable reproductive health information to citizens who may postpone health management due to busy lifestyles. We aim to contribute to the spread of a culture where individuals understand and actively manage their reproductive health."
Recently, LG Chem also held a diabetes awareness campaign at LG Science Park in Gangseo-gu, Seoul. Employees received the official mascot doll 'Dangdang-i' from the Korean Diabetes Association and campaign slogan keychains to raise awareness about diabetes.
Meanwhile, LG Chem announced on November 5 that it recorded provisional third-quarter sales of 15.496 trillion won and an operating profit of 561.2 billion won. Compared to the same period last year, sales increased by 34%, while operating profit decreased by 17.4%. Compared to the previous quarter (Q2), sales rose by 9.3%, but operating profit fell by 6.4%.
The life sciences division reported sales of 337.3 billion won and an operating profit of 23.2 billion won. The decline in sales and profitability was attributed to reduced export shipment volumes and increased R&D costs compared to the previous quarter. In the fourth quarter, sales and profitability are expected to improve due to concentrated export volumes of certain products, including vaccines, and the receipt of additional advance payments following the signing of a licensing agreement for a rare obesity treatment.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.